Literature DB >> 17069916

The biological effectiveness of antiproton irradiation.

Michael H Holzscheiter1, Niels Bassler, Nzhde Agazaryan, Gerd Beyer, Ewart Blackmore, John J DeMarco, Michael Doser, Ralph E Durand, Oliver Hartley, Keisuke S Iwamoto, Helge V Knudsen, Rolf Landua, Carl Maggiore, William H McBride, Søren Pape Møller, Jørgen Petersen, Lloyd D Skarsgard, James B Smathers, Timothy D Solberg, Ulrik I Uggerhøj, Sanja Vranjes, H Rodney Withers, Michelle Wong, Bradly G Wouters.   

Abstract

BACKGROUND AND
PURPOSE: Antiprotons travel through tissue in a manner similar to that for protons until they reach the end of their range where they annihilate and deposit additional energy. This makes them potentially interesting for radiotherapy. The aim of this study was to conduct the first ever measurements of the biological effectiveness of antiprotons.
MATERIALS AND METHODS: V79 cells were suspended in a semi-solid matrix and irradiated with 46.7MeV antiprotons, 48MeV protons, or (60)Co gamma-rays. Clonogenic survival was determined as a function of depth along the particle beams. Dose and particle fluence response relationships were constructed from data in the plateau and Bragg peak regions of the beams and used to assess the biological effectiveness.
RESULTS: Due to uncertainties in antiproton dosimetry we defined a new term, called the biologically effective dose ratio (BEDR), which compares the response in a minimally spread out Bragg peak (SOBP) to that in the plateau as a function of particle fluence. This value was approximately 3.75 times larger for antiprotons than for protons. This increase arises due to the increased dose deposited in the Bragg peak by annihilation and because this dose has a higher relative biological effectiveness (RBE).
CONCLUSION: We have produced the first measurements of the biological consequences of antiproton irradiation. These data substantiate theoretical predictions of the biological effects of antiproton annihilation within the Bragg peak, and suggest antiprotons warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17069916     DOI: 10.1016/j.radonc.2006.09.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Particle radiation therapy for gastrointestinal malignancies.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Gastrointest Cancer Res       Date:  2007

2.  Evaluation on Geant4 Hadronic Models for Pion Minus, Pion Plus and Neutron Particles as Major Antiproton Annihilation Products.

Authors:  Mohammad Bagher Tavakoli; Mohammad Mehdi Mohammadi; Reza Reiazi; Keyvan Jabbari
Journal:  J Med Signals Sens       Date:  2015 Apr-Jun

3.  Comparison of electromagnetic and hadronic models generated using Geant 4 with antiproton dose measured in CERN.

Authors:  Mohammad Bagher Tavakoli; Reza Reiazi; Mohammad Mehdi Mohammadi; Keyvan Jabbari
Journal:  J Med Phys       Date:  2015 Apr-Jun

4.  (210)Po microsphere radiological design for tumor vascular disruption.

Authors:  J J Bevelacqua
Journal:  PeerJ       Date:  2015-08-04       Impact factor: 2.984

5.  Antiproton induced DNA damage: proton like in flight, carbon-ion like near rest.

Authors:  J N Kavanagh; F J Currell; D J Timson; K I Savage; D J Richard; S J McMahon; O Hartley; G A P Cirrone; F Romano; K M Prise; N Bassler; M H Holzscheiter; G Schettino
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

6.  Tumor vascular disruption using various radiation types.

Authors:  Jj Bevelacqua
Journal:  PeerJ       Date:  2014-04-01       Impact factor: 2.984

7.  Neutron activation of gadolinium for ion therapy: a Monte Carlo study of charged particle beams.

Authors:  Kurt W Van Delinder; Rao Khan; James L Gräfe
Journal:  Sci Rep       Date:  2020-08-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.